Phio Pharmaceuticals (PHIO) Cash from Operations (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Cash from Operations came in at 4003000.0 in Q1 2026, down 213.96% YoY from 3512611.84 in Q1 2025, and down 92.54% on a QoQ basis from 2079000.0 in Q4 2025.
Phio Pharmaceuticals (PHIO) Cash from Operations (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Cash from Operations data on file, last reported at 4003000.0 in Q1 2026.
- Quarterly Cash from Operations fell 213.96% year-over-year to 4003000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10707000.0 (down 67.93% YoY) and the FY2025 annual result came in at 7979000.0, down 12.19% from the prior year.
- Cash from Operations slipped to 4003000.0 in Q1 2026, from 2079000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1275000.0 in Q1 2025 to a low of 4003000.0 in Q1 2026.
- A 5-year average of 2468941.18 and a median of 2429000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations surged 42.15% — and 2026, when it sank 213.96%.
- Tracing PHIO's Cash from Operations over 5 years: stood at 2705000.0 in 2022, then rose by 12.38% to 2370000.0 in 2023, then surged by 42.15% to 1371000.0 in 2024, then plunged by 51.64% to 2079000.0 in 2025, then tumbled by 92.54% to 4003000.0 in 2026.
- The last three Cash from Operations figures came in at 4003000.0 (Q1 2026), 2079000.0 (Q4 2025), and 2085000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | -4.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.04 Mn |
| Jun 30, 2026 | -4.04 Mn |
| Mar 31, 2026 | -4.00 Mn |
| Mar 31, 2026 | -4.00 Mn |
| Dec 31, 2025 | -2.08 Mn |
| Dec 31, 2025 | -2.08 Mn |
| Sep 30, 2025 | -2.09 Mn |
| Sep 30, 2025 | -2.09 Mn |
| Jun 30, 2025 | -2.54 Mn |
| Jun 30, 2025 | -2.54 Mn |
| Mar 31, 2025 | -1.28 Mn |
| Mar 31, 2025 | -1.28 Mn |
| Dec 31, 2024 | -1.37 Mn |
| Dec 31, 2024 | -1.37 Mn |
| Sep 30, 2024 | -1.95 Mn |
| Sep 30, 2024 | -1.95 Mn |
| Jun 30, 2024 | -1.78 Mn |
| Jun 30, 2024 | -1.78 Mn |
| Mar 31, 2024 | -2.01 Mn |
| Mar 31, 2024 | -2.01 Mn |